Tocilizumab (ACTEMRA) ELISA Assay Kit
The Tocilizumab (ACTEMRA) ELISA Assay Kit is For Research Use Only
Size: 12 x 8 wells
Sensitivity: 0.003 ug/mL
Standard Range: 0 – 3000 ng/mL
Incubation Time: 1 hour 10 minutes
Sample Type: Serum, Plasma
Sample Size: 20 µL
Alternative Name: Actemra
Assay Background
Tocilizumab is a recombinant, humanized, anti-human interleukin 6 (IL-6) receptor monoclonal antibody that achieves a significant therapeutic response rate. The light chain is made up of 214 amino acids. The heavy chain is made up of 448 amino acids. The four polypeptide chains are linked intra- and inter- molecularly by disulfide bonds. FDA approved on January 8, 2010. Tocilizumab (injection) was further approved by the FDA for the treatment of adults with giant cell arteritis, an inflammation of the blood vessels (vasculitis) in May, 2017. In a double-blind, placebo-controlled study, the patients achieved sustained remission from Week 12 through Week 52, which was associated with significant improvements in symptoms of giant cell arteritis, normalization of inflammatory laboratory tests and tapering the use of corticosteroids. Interleukin (IL)-6 plays essential roles not only in the immune response, but also in haematopoiesis and the central nervous system. Unregulated production of IL-6 has been found in chronic inflammatory autoimmune diseases, such as rheumatoid arthritis (RA), systemic onset juvenile idiopathic arthritis (soJIA), Crohn’s disease (CD), systemic lupus erythematosus (SLE) and vasculitis. Furthermore, IL-6 activities can explain many symptoms of these diseases. More importantly, serum levels of IL-6 are correlated with disease activity. Tocilizumab binds specifically to both soluble and membrane-bound IL-6 receptors (sll-6R and mll-6R), and has been shown to inhibit IL-6-mediated signaling through these receptors.
Assay Principle
Solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. Standards and samples (serum or plasma) are incubated in the microtiter plate coated with the reactant for tocilizumab. After incubation, the wells are washed. Then, horse radish peroxidase (HRP) conjugated probe is added and binds to tocilizumab captured by the reactant on the surface of the wells. Following incubation wells are washed and the bound enzymatic activity is detected by addition of tetramethylbenzidine (TMB) chromogen substrate. Finally, the reaction is terminated with an acidic stop solution. The color developed is proportional to the amount of tocilizumab in the sample or standard. Results of samples can be determined directly using the standard curve.
Related Products
Tocilizumab mAb-based ELISA Assay
Eculizumab (Soliris) ELISA Kit
